The results of the November elections portend important changes to our healthcare industry. We expect the new Congress’ first action to be the repeal of certain portions of the Affordable Care Act. While we do not expect this to have…
Now is time for all Covered Entities participating in the 340B Drug Pricing Program – the key stakeholders – to pay close attention to the November elections. Collectively, the White House, Senate and House of Representatives have the power to…
Lorem ipsum dolor sit amet, eu eam aeque exerci delicatissimi, vocibus signiferumque ea eos. Quo ea rebum liberavisse. Libris vidisse feugiat te vel, ea est facilisi dissentias efficiantur. Vero labitur democritum has id, an nibh iriure blandit vim, ut est…
Lorem ipsum dolor sit amet, eu eam aeque exerci delicatissimi, vocibus signiferumque ea eos. Quo ea rebum liberavisse. Libris vidisse feugiat te vel, ea est facilisi dissentias efficiantur. Vero labitur democritum has id, an nibh iriure blandit vim, ut est…
Lorem ipsum dolor sit amet, eu eam aeque exerci delicatissimi, vocibus signiferumque ea eos. Quo ea rebum liberavisse. Libris vidisse feugiat te vel, ea est facilisi dissentias efficiantur. Vero labitur democritum has id, an nibh iriure blandit vim, ut est…
Lorem ipsum dolor sit amet, eu eam aeque exerci delicatissimi, vocibus signiferumque ea eos. Quo ea rebum liberavisse. Libris vidisse feugiat te vel, ea est facilisi dissentias efficiantur. Vero labitur democritum has id, an nibh iriure blandit vim, ut est…
Being aware of the complex and ever-changing 340B Drug Pricing Program rules helps covered entities maintain integrity and drive program value. Successful 340B programs focus on three fundamental objectives; ensuring compliance, optimizing savings and controlling skyrocketing costs of pharmaceuticals. It’s…
Sandbox Environment.